Othera Pharmaceuticals
Othera Pharmaceuticals is a Conshohocken, PA-based specialty pharmaceutical company founded in 2002, historically focused on developing ophthalmic disease therapeutics. No active products, recent funding, or operational signals are documented; the company domain is currently listed for sale.
- Company typePrivate
- Founded2002
- HeadquartersConshohocken, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Othera Pharmaceuticals does
Othera Pharmaceuticals is a specialty pharmaceutical company founded in 2002 and headquartered in Conshohocken, Pennsylvania, that has historically focused on developing treatments for ophthalmic diseases. Based on the firm's stated focus and R&D leadership structure (Chairman & CEO David Joseph, EVP & CSO William Matier, VP of R&D Ghanshyam Patil), the company's underlying activity appears to have been small-molecule therapeutic research targeted at eye disorders, supported by approximately $23.6 million in total disclosed venture funding across two rounds in 2004 and 2009 from investors including NewSpring Ventures, Johnson & Johnson Development Corporation, and Liberty Venture Partners.
No product pipeline, approved drugs, pricing structure, distribution channels, customer relationships, or revenue figures are documented in the available source material. The company's web domain (othera.com) currently displays a "domain may be for sale" notice and Above.com's generic Privacy Policy and Terms of Use, with no Othera-specific content. No patents, trademarks, partnerships, awards, regulatory actions, M&A activity, or leadership transitions are recorded in the input data, and the last funding event is dated August 2009.
The business model cannot be confirmed from the data provided. As a private specialty pharmaceutical developer with 11–50 listed employees and no observed commercial revenue signals, the implied model would be R&D-stage drug development reliant on venture financing and potential future licensing or commercialization partnerships. However, the absence of any post-2009 funding, product, or operational update, combined with the parked domain, indicates the company is likely no longer actively operating in a conventional sense.
Othera Pharmaceuticals firmographics
Firmographics- Name
- Othera Pharmaceuticals
- Website
- https://othera.com
- Company type
- Private
- Founded year
- 2002
- Headcount range
- 11–50 employees
- Short description
- Othera Pharmaceuticals is a Conshohocken, PA-based specialty pharmaceutical company founded in 2002, historically focused on developing ophthalmic disease therapeutics. No active products, recent funding, or operational signals are documented; the company domain is currently listed for sale.
- Ownership category
- akta.pro rank
Othera Pharmaceuticals industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where Othera Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Conshohocken
- HQ country
- United States
- HQ region
- North America
Markets served
Othera Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Othera Pharmaceuticals product offering
Product offeringCore offering
Othera Pharmaceuticals is a specialty pharmaceutical company focused on developing treatments for ophthalmic (eye) diseases. The company operates a small R&D-driven organization (11–50 employees) with a Chief Science Officer and VP of R&D, implying research and development of ophthalmic therapeutics for eventual commercialization. Specific product names, indications, and pipeline details are not evidenced in the available source data.
Product overview
No product information available. The domain othera.com displays a "domain may be for sale" notice with no content related to Othera Pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Companies that use Othera Pharmaceuticals
Customer profileIdeal customer profiles1 record
Othera Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Othera Pharmaceuticals partnerships and signals
Strategic signalRecent moves2 records
Othera Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Kodiak Sciences: A clinical-stage biotech developing ophthalmology therapeutics (notably retinal vascular diseases), comparable as a venture-backed ophthalmology-focused pharmaceutical developer.
- Apellis Pharmaceuticals: An emerging ophthalmology-focused biotech with approved retinal disease therapies (e.g., Syfovre/Empaveli), representing the type of newer specialty-pharma entrant Othera could have competed alongside.
- Oxurion (formerly ThromboGenics): A specialty ophthalmology biopharmaceutical company developing treatments for retinal disorders — directly comparable in therapeutic focus and company scale.
Broad incumbents
- Bausch + Lomb: A long-established, large ophthalmology player covering prescription ophthalmic pharmaceuticals, surgical devices, and consumer eye-health products — directly overlapping Othera's specialty-pharma category at much greater scale.
- Alcon: A global leader in eye care with a significant ophthalmic pharmaceuticals franchise (including anti-infectives, anti-inflammatories, and dry-eye treatments), competing in the same therapeutic categories Othera targets.
- Regeneron Pharmaceuticals: Develops and commercializes Eylea, the market-leading anti-VEGF therapy for retinal diseases — a flagship ophthalmology pharmaceutical product that defines the competitive landscape Othera would have entered.
- Novartis Pharmaceuticals (Ophthalmology): Through products such as Lucentis, Novartis is a major player in retinal disease and broader ophthalmology pharmaceuticals, setting the standard for commercial execution in the space.
- AbbVie (Allergan Aesthetics / Eye Care): Through its acquisition of Allergan, AbbVie holds a broad ophthalmology pharmaceutical portfolio (e.g., Ozurdex, Alphagan) spanning retinal, glaucoma, and dry-eye conditions.
Direct peers
- Santen Pharmaceutical: A Japan-based specialty pharmaceutical company entirely focused on ophthalmology, with prescription treatments across glaucoma, dry eye, and retinal disease — highly comparable in mission and product scope.
- Aerie Pharmaceuticals: A specialty pharmaceutical company focused on ophthalmic therapies (notably glaucoma and dry eye), making it one of the closest comparables to Othera's stated ophthalmology specialty-pharma focus.
Market position
Strengths1 record
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights3 records
Customer concentration
Othera Pharmaceuticals social profiles
Digital presenceOthera Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Othera Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles3 records
Othera Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Othera Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Othera Pharmaceuticals
What does Othera Pharmaceuticals do?
Othera Pharmaceuticals is a specialty pharmaceutical company focused on developing treatments for ophthalmic (eye) diseases. The company operates a small R&D-driven organization (11–50 employees) with a Chief Science Officer and VP of R&D, implying research and development of ophthalmic therapeutics for eventual commercialization. Specific product names, indications, and pipeline details are not evidenced in the available source data.
When was Othera Pharmaceuticals founded?
Othera Pharmaceuticals was founded in 2002. It employs 11 to 50 people.
Where is Othera Pharmaceuticals based?
Othera Pharmaceuticals is headquartered in Conshohocken, United States, in the North America region.
Who are Othera Pharmaceuticals's main competitors?
Emerging players on record are Kodiak Sciences, Apellis Pharmaceuticals and Oxurion (formerly ThromboGenics). Broad incumbents are Bausch + Lomb, Alcon, Regeneron Pharmaceuticals, Novartis Pharmaceuticals (Ophthalmology) and AbbVie (Allergan Aesthetics / Eye Care). Direct peers are Santen Pharmaceutical and Aerie Pharmaceuticals.
Does Othera Pharmaceuticals have an API?
No public API is recorded for Othera Pharmaceuticals.
What industry is Othera Pharmaceuticals in?
Othera Pharmaceuticals's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.